Intersect ENT, Inc. (XENT) Receives Consensus Rating of “Buy” from Brokerages

Shares of Intersect ENT, Inc. (NASDAQ:XENT) have been given an average rating of “Buy” by the thirteen ratings firms that are covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $30.57.

Several analysts have issued reports on XENT shares. Zacks Investment Research upgraded shares of Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research report on Thursday, October 5th. Canaccord Genuity upped their price target on shares of Intersect ENT from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Wednesday, September 13th. Bank of America Corporation upped their price target on shares of Intersect ENT from $33.00 to $40.00 and gave the company a “buy” rating in a research report on Monday, September 11th. Piper Jaffray Companies restated a “buy” rating and set a $35.00 price target on shares of Intersect ENT in a research report on Tuesday, August 22nd. Finally, Deutsche Bank AG set a $31.00 price objective on shares of Intersect ENT and gave the company a “buy” rating in a research note on Wednesday, August 2nd.

In related news, COO Richard E. Kaufman sold 22,425 shares of the stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $30.22, for a total value of $677,683.50. Following the completion of the transaction, the chief operating officer now directly owns 149,821 shares of the company’s stock, valued at $4,527,590.62. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Jeryl L. Hilleman sold 12,833 shares of the stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $31.05, for a total transaction of $398,464.65. Following the completion of the transaction, the chief financial officer now directly owns 27,833 shares of the company’s stock, valued at $864,214.65. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 136,263 shares of company stock valued at $4,007,798. Insiders own 13.70% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Oppenheimer Asset Management Inc. bought a new position in Intersect ENT in the third quarter worth about $117,000. Great West Life Assurance Co. Can bought a new position in Intersect ENT in the third quarter worth about $116,000. Legal & General Group Plc raised its stake in Intersect ENT by 3.8% in the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock worth $193,000 after buying an additional 255 shares in the last quarter. Moors & Cabot Inc. bought a new position in Intersect ENT in the second quarter worth about $205,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in Intersect ENT in the third quarter worth about $228,000. 87.22% of the stock is owned by institutional investors.

Shares of Intersect ENT (NASDAQ XENT) opened at $29.90 on Friday. Intersect ENT has a 1 year low of $9.20 and a 1 year high of $33.25.

Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative net margin of 19.81% and a negative return on equity of 15.96%. The business had revenue of $22.31 million during the quarter, compared to analyst estimates of $21.53 million. During the same period in the prior year, the business posted ($0.22) earnings per share. The company’s revenue was up 20.8% on a year-over-year basis. equities analysts expect that Intersect ENT will post -0.63 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Intersect ENT, Inc. (XENT) Receives Consensus Rating of “Buy” from Brokerages” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/11/26/intersect-ent-inc-xent-receives-consensus-rating-of-buy-from-brokerages.html.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply